RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
This invention relates to compounds, compositions, and methods useful for modulating human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of human immunodeficiency virus (HIV) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of HIV genes. The small nucleic acid molecules are useful in the treatment of HIV infection, AIDS, and/or disease and conditions related to HIV infection and/or AIDS in a subject or organism.
1. A chemically modified short interfering nucleic acid (siNA) molecule, wherein:
a) the siNA comprises a sense strand and an antisense strand;
b) each strand is independently 18 to 24 nucleotides in length, and together comprise a duplex having between 17 and 23 base pairs;
c) the antisense strand is complementary to a human immunodeficiency virus (HIV) RNA sequence;
d) a plurality of pyrimidine nucleotides present in the sense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and a plurality of purine nucleotides present in the sense strand are 2′-deoxy purine nucleotides; and
e) a plurality of pyrimidine nucleotides in the antisense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides and a plurality of purine nucleotides present in the antisense strand are 2′-O-methyl purine nucleotides.
2. The siNA molecule of claim 1 , wherein the sense strand has a cap at both 5′- and 3′-ends of the sense strand.
3. The siNA molecule of claim 1 , comprising a 3′-overhang on one or both strands.
4. The siNA molecule of claim 1 , wherein the siNA comprises one or more phosphorothioate internucleotide linkages.
5. A composition comprising the siNA molecule of claim 1 and a pharmaceutically acceptable carrier or diluent.